At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Intranasal Insulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome
In Brief
A Phase 2 clinical trial evaluating Intranasal Insulin and Placebo for Tobacco Abstinence Syndrome. Completed, enrolled 51 participants across 1 site.
Detailed Summary
This study will evaluate safety and efficacy of intranasal insulin in abstinent smokers. Groups' (placebo vs. insulin) cognitive function and stress response will be compared.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTobacco Abstinence Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartAug 2013
Primary CompletionMay 2016
TodayJul 2026
First PostedJan 31, 2013
Enrollment StartAug 1, 2013
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.4 years ago
Interventions
Intranasal Insulindrug
Placebodrug